Fulcrum Therapeutics (FULC) Cash from Operations (2018 - 2026)
Fulcrum Therapeutics (FULC) reported Cash from Operations of 18750000.0 for Q1 2026, down 22.89% year-over-year from 24317302.79 in Q1 2025, and down 11.62% quarter-over-quarter from 16798000.0 in Q4 2025.
Fulcrum Therapeutics (FULC) Cash from Operations (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has 9 years of Cash from Operations data on file, last reported at 18750000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 18750000.0, down 22.89% year-over-year; the trailing twelve-month figure through Mar 2026 was 63558000.0 (down 913.91% YoY), and the FY2025 annual result was 60065000.0, down 2608.07% from the prior year.
- Cash from Operations fell to 18750000.0 in Q1 2026 per FULC's latest filing, from 16798000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 58899000.0 in Q2 2024 and troughed at 27882000.0 in Q3 2022.
- A 5-year average of 15826352.94 and a median of 19696000.0 in 2022 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations surged 383.37% in 2024, then tumbled 123.46% in 2025.
- A 5-year view of Cash from Operations shows it stood at 19696000.0 in 2022, then retreated by 17.58% to 23158000.0 in 2023, then climbed by 27.62% to 16761000.0 in 2024, then dropped by 0.22% to 16798000.0 in 2025, then dropped by 11.62% to 18750000.0 in 2026.
- Business Quant data shows FULC's Cash from Operations at 18750000.0 in Q1 2026, 16798000.0 in Q4 2025, and 14190000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Fulcrum Therapeutics | 267.90 Mn | 267.90 Mn | - | -18.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.75 Mn |
| Mar 31, 2026 | -18.75 Mn |
| Dec 31, 2025 | -16.80 Mn |
| Dec 31, 2025 | -16.80 Mn |
| Sep 30, 2025 | -14.19 Mn |
| Sep 30, 2025 | -14.19 Mn |
| Jun 30, 2025 | -13.82 Mn |
| Jun 30, 2025 | -13.82 Mn |
| Mar 31, 2025 | -15.26 Mn |
| Mar 31, 2025 | -15.26 Mn |
| Dec 31, 2024 | -16.76 Mn |
| Dec 31, 2024 | -16.76 Mn |
| Sep 30, 2024 | -19.07 Mn |
| Sep 30, 2024 | -19.07 Mn |
| Jun 30, 2024 | 58.90 Mn |
| Jun 30, 2024 | 58.90 Mn |
| Mar 31, 2024 | -25.28 Mn |
| Mar 31, 2024 | -25.28 Mn |
| Dec 31, 2023 | -23.16 Mn |
| Dec 31, 2023 | -23.16 Mn |